Robert W. Baird analyst Eric Coldwell maintained a Buy rating on PRA Health Sciences (NASDAQ: PRAH) today and set a price target of $116. The company’s shares closed yesterday at $109.24, close to its 52-week high of $109.54.
According to TipRanks.com, Coldwell is a 4-star analyst with an average return of 7.5% and a 53.2% success rate. Coldwell covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Quest Diagnostics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PRA Health Sciences with a $112.83 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $109.54 and a one-year low of $73.23. Currently, PRA Health Sciences has an average volume of 721.9K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutios segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services.
